Marlene Gyldmark

455 total citations
33 papers, 374 citations indexed

About

Marlene Gyldmark is a scholar working on Economics and Econometrics, Pulmonary and Respiratory Medicine and Epidemiology. According to data from OpenAlex, Marlene Gyldmark has authored 33 papers receiving a total of 374 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Economics and Econometrics, 9 papers in Pulmonary and Respiratory Medicine and 8 papers in Epidemiology. Recurrent topics in Marlene Gyldmark's work include Influenza Virus Research Studies (8 papers), Health Systems, Economic Evaluations, Quality of Life (8 papers) and Lung Cancer Treatments and Mutations (8 papers). Marlene Gyldmark is often cited by papers focused on Influenza Virus Research Studies (8 papers), Health Systems, Economic Evaluations, Quality of Life (8 papers) and Lung Cancer Treatments and Mutations (8 papers). Marlene Gyldmark collaborates with scholars based in Switzerland, United Kingdom and United States. Marlene Gyldmark's co-authors include Gwendolyn C. Morrison, Keith Tolley, Beate Sander, James Creeden, Frederick G. Hayden, Anita Alban, Jes Søgaard, Ebba Holme Hansen, Michael Peake and Louis P. Garrison and has published in prestigious journals such as Blood, Social Science & Medicine and AIDS.

In The Last Decade

Marlene Gyldmark

29 papers receiving 362 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Marlene Gyldmark Switzerland 13 143 115 63 58 50 33 374
Richéal Burns United Kingdom 10 105 0.7× 57 0.5× 42 0.7× 62 1.1× 75 1.5× 22 346
Elle Pope United States 7 97 0.7× 74 0.6× 38 0.6× 43 0.7× 13 0.3× 15 257
Michael Klein United States 12 38 0.3× 57 0.5× 61 1.0× 44 0.8× 94 1.9× 31 423
Rotimi David Nigeria 8 64 0.4× 79 0.7× 117 1.9× 74 1.3× 152 3.0× 23 476
Abdoulaye Diédhiou Senegal 11 38 0.3× 54 0.5× 44 0.7× 90 1.6× 39 0.8× 42 334
Alexander Iseolorunkanmi United Kingdom 3 53 0.4× 41 0.4× 76 1.2× 72 1.2× 56 1.1× 6 290
C. L. Bennett United States 10 59 0.4× 57 0.5× 47 0.7× 33 0.6× 79 1.6× 27 307
Kathleen McDavid United States 11 80 0.6× 115 1.0× 135 2.1× 75 1.3× 198 4.0× 17 500
Pragati Advani United States 6 201 1.4× 77 0.7× 34 0.5× 51 0.9× 217 4.3× 10 436
Ahmad Faramarzi Iran 9 62 0.4× 25 0.2× 35 0.6× 61 1.1× 32 0.6× 20 249

Countries citing papers authored by Marlene Gyldmark

Since Specialization
Citations

This map shows the geographic impact of Marlene Gyldmark's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marlene Gyldmark with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marlene Gyldmark more than expected).

Fields of papers citing papers by Marlene Gyldmark

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marlene Gyldmark. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marlene Gyldmark. The network helps show where Marlene Gyldmark may publish in the future.

Co-authorship network of co-authors of Marlene Gyldmark

This figure shows the co-authorship network connecting the top 25 collaborators of Marlene Gyldmark. A scholar is included among the top collaborators of Marlene Gyldmark based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marlene Gyldmark. Marlene Gyldmark is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Tatt, Iain, et al.. (2019). Timely, consistent, transparent assessment of market access evidence: implementing tools based on the HTA Core Model® in a pharmaceutical company. International Journal of Technology Assessment in Health Care. 35(1). 10–16. 5 indexed citations
3.
Giuliani, Giovanni, et al.. (2018). Leveraging EUnetHTA’s conceptual framework to compare HTA decision drivers in France, Italy, and Germany from a manufacturer’s point of view. Health Economics Review. 8(1). 24–24. 8 indexed citations
4.
Gyldmark, Marlene, et al.. (2018). IS THE EUNETHTA HTA CORE MODEL® FIT FOR PURPOSE? EVALUATION FROM AN INDUSTRY PERSPECTIVE. International Journal of Technology Assessment in Health Care. 34(5). 458–463. 13 indexed citations
5.
Gyldmark, Marlene, et al.. (2018). PP18 An Access Evidence IT Solution Within A Pharmaceutical Company. International Journal of Technology Assessment in Health Care. 34(S1). 72–73. 1 indexed citations
6.
Vlaenderen, Ilse Van, J.-L. Canon, V. Cocquyt, et al.. (2009). TRASTUZUMAB TREATMENT OF EARLY STAGE BREAST CANCER IS COST-EFFECTIVE FROM THE PERSPECTIVE OF THE BELGIAN HEALTH CARE AUTHORITIES. Acta Clinica Belgica. 64(2). 100–112. 19 indexed citations
7.
8.
9.
10.
Novák, Annoesjka, et al.. (2007). PD6-3-5: Pharmacoeconomic analysis shows that erlotinib is cost-saving versus docetaxel, and cost-effective versus best supportive care (BSC) in NSCLC. Journal of Thoracic Oncology. 2(8). S433–S433. 2 indexed citations
11.
Orlewska, Ewa, et al.. (2007). PCN7 COST-EFFECTIVENESS ANALYSIS OF ADJUVANT THERAPY WITH TRASTUZUMAB FOR HER2-POSITIVE EARLY BREAST CANCER IN POLISH SETTING. Value in Health. 10(3). A125–A125. 1 indexed citations
12.
Bettis, Robert, et al.. (2006). Impact of Influenza Treatment with Oseltamivir on Health, Sleep and Daily Activities of Otherwise Healthy Adults and Adolescents. Clinical Drug Investigation. 26(6). 329–340. 28 indexed citations
13.
Sander, Beate, Frederick G. Hayden, Marlene Gyldmark, & Louis P. Garrison. (2006). Post-Exposure Influenza Prophylaxis with Oseltamivir. PharmacoEconomics. 24(4). 373–386. 20 indexed citations
14.
Sander, Beate, et al.. (2005). Influenza treatment with neuraminidase inhibitors. The European Journal of Health Economics. 6(3). 244–252. 14 indexed citations
15.
Reisinger, Keith S., et al.. (2004). Effect of Influenza Treatment with Oseltamivir on Health Outcome and Costs in Otherwise Healthy Children. Clinical Drug Investigation. 24(7). 395–407. 21 indexed citations
16.
Gyldmark, Marlene & Gwendolyn C. Morrison. (2001). Demand for health care in Denmark: results of a national sample survey using contingent valuation. Social Science & Medicine. 53(8). 1023–1036. 32 indexed citations
17.
Alban, Anita, et al.. (1997). The Danish Approach to Standards For Economic Evaluation Methodologies. PharmacoEconomics. 12(6). 627–636. 24 indexed citations
18.
Postma, Maarten J., Reiner Leidl, Angela M. Downs, et al.. (1993). Economic impact of the AIDS epidemic in the European Community. AIDS. 7(4). 541–554. 18 indexed citations
19.
Tolley, Keith & Marlene Gyldmark. (1993). The treatment and care costs of people with HIV infection or AIDS: development of a standardised cost framework for Europe. Health Policy. 24(1). 55–70. 24 indexed citations
20.
Morrison, Gwendolyn C. & Marlene Gyldmark. (1992). Appraising the use of contingent valuation. Health Economics. 1(4). 233–243. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Richéal Burns Breakdown of academic impact, for papers by Elle Pope Breakdown of academic impact, for papers by Michael Klein Breakdown of academic impact, for papers by Rotimi David Breakdown of academic impact, for papers by Abdoulaye Diédhiou Breakdown of academic impact, for papers by Alexander Iseolorunkanmi Breakdown of academic impact, for papers by C. L. Bennett Breakdown of academic impact, for papers by Kathleen McDavid Breakdown of academic impact, for papers by Pragati Advani Breakdown of academic impact, for papers by Ahmad Faramarzi
Rankless by CCL
2026